BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:34 PM
 | 
Feb 19, 2009
 |  BC Extra  |  Company News

FDA wants additional Firazyr trial

Shire (LSE:SHP; NASDAQ:SHPGY) said FDA will require an additional Phase III trial of Firazyr icatibant to treat hereditary angioedema (HAE). The company said it expects to start the trial in the third quarter and submit its response to...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >